ELAN News

Animal parasiticides market to grow at a CAGR of 6% during the forecast period (2025 – 2030): Wissen Research

Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs

Feline Hyperthyroidism: Virbac acquires Felanorm

Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity

Elanco Investor Day Defines New Era as Sustainable Growth Company

$71.83 Animal Health Market - Global Forecasts from 2025 to 2030: Key Opportunities Lie in R&D for Innovative Products, Supportive Policies, and Expanding Distribution Networks & E-commerce Channels

Elanco executive appointed as Neurizon's Board Observer USA - English USA - English

Elanco executive appointed as Neurizon's Board Observer USA - English USA - English

Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference